LENA DEGLING WIKINGSSON, PhD (Chairman)
Lena Degling Wikingsson is a pharmacist by training and holds a PhD in Pharmaceutical Science. She has over 20 years of experience in the pharmaceutical industry and has previously been CEO of Independent Pharmaceutica AB and Avaris AB, a non-executive Director of Avaris AB, held positions at SBL Vaccines, Accuro Immunology, and worked as a biotechnology assessor at the Medicinal Products Agency. She has broad experience in regulatory affairs and development of biologics and vaccines. Lena Degling Wikingsson is currently non-executive Director of Simplexia and CEO of Dilafor AB.
GUNNAR MATTSON, LL.M
Gunnar Mattsson is Partner of Advokatfirman Lindahl, one of Sweden’s largest law firms, since 1994. Head of Lindahl’s life sciences practice 2009-2014. Internationally ranked as a leading lawyer within life sciences. Extensive experience as director of public and private companies within pharmaceuticals and biotechnology.
HANS GUSTAF LJUNGGREN, MD, PhD
Hans-Gustaf Ljunggren serves as a Professor at Karolinska Institutet and is the Founder of the Centre for Infectious Medicine (CIM) and former Dean of Research at Karolinska Institutet. His research field is immunology, in particular early immune reactions in infectious and malignant diseases. He has had a long-term interest in exploring the molecular specificity, function, and therapeutic potential of human NK cells in different disease settings.
Agneta Edberg, has over 25 years’ experience from leading positions in life science industry. She has been CEO at Mylan AB and the Swedish Pharmaceutical Insurance and has held leading positions within Pfizer, Bactiguard och Cilag (Johnson & Johnson). Agneta has between 2010 – 2018 been chairman of the board of Immunicum AB a company active within immune oncology and listed on the Stockholm Stock Exchange. She is also chairman of the board of Idogen AB and participate on the board of the VINNOVA project CAMP, Centre for Advanced Medical Products to cover the needs of SMEs.